Agios Pharmaceuticals, Inc.

A few months after restructuring to conserve cash and put primary focus on its lead candidate BDTX-1535 in first-line non-small cell lung cancer, Black Diamond Therapeutics found a lifeline in Servier

Astellas Is Looking For Bolt-On Deals Astellas Pharma is looking to add new assets to its pipeline that could launch in the late 2020s or early in the next decade, chief strategy officer Adam Pearson

Novo Nordisk acquired its pyruvate kinase-R (PKR) activator etavopivat when it bought Forma Therapeutics for $1.1bn to expand its portfolio in rare hemoglobinopathies outside of hemophilia. At the Ame

This year’s American Society of Hematology (ASH) meeting delivered positive Phase II results for a new daily oral therapy and promising interim Phase I/II data for a one-time base editing treatment fo